Impact of Omalizumab On All-Cause and Asthma-Related Health Care Resource Utilisation in Patients With Moderate or Severe Persistent Asthma.
نویسندگان
چکیده
منابع مشابه
Benefits of omalizumab on anxiety and depression in patients with severe asthma
Background: Asthma is one of the most common chronic diseases and may cause psychiatric disorders affecting the patients’ quality of life. In our study, we evaluated the effect of omalizumab treatment on anxiety disorder and depression using Beck Depression Scale (BDS) and State Trait Anxiety Inventory (STAI). Methods: Anxiety level was determined with STAI, whereas depression level was ...
متن کاملImpact of omalizumab on treatment of severe allergic asthma in UK clinical practice: a UK multicentre observational study (the APEX II study)
OBJECTIVE To describe the impact of omalizumab on asthma management in patients treated as part of normal clinical practice in the UK National Health Service (NHS). DESIGN A non-interventional, mixed methodology study, combining retrospective and prospective data collection for 12 months pre-omalizumab and post-omalizumab initiation, respectively. SETTING Data were collected in 22 UK NHS ce...
متن کاملEvaluation of Omeprazole in the Treatment of Moderate to Severe Persistent Asthma in Children
Background and Objective: Asthma is the most common chronic disease of childhood. The disease is caused by a temporary blockage of airflow due to chronic inflammation of the airways . One of the conditions that often occur with asthma and exacerbate disease, is gastroesophageal reflux. The aim of this study is to evaluate the role of acid suppressing therapy in patients with refractory asthma...
متن کاملEfficacy of omalizumab (Xolair®) in patients with moderate to severe predominately chronic oral steroid dependent asthma in Taiwan: a retrospective, population-based database cohort study
BACKGROUND Omalizumab (Xolair®), a recombinant monoclonal anti-IgE antibody, has demonstrated efficacy in clinical trials conducted in patients with moderate to severe persistent allergic asthma. We aimed to investigate the efficacy, discontinuation and medical resource utilization of omalizumab in the real-life setting in Taiwan. METHODS This study was a retrospective, population-based datab...
متن کاملXolair® (omalizumab) enrollment in a tertiary care allergy and asthma clinic in Canada
Background Xolair ® (omalizumab) has been approved in Canada since 2004 for the treatment of moderate to severe persistent allergic asthma in patients 12 years of age. The use of omalizumab in severe persistent allergic asthma may lead to decrease health care utilization through emergency room (ER) visits, hospitalizations, visits to health care providers, as well as, decrease the use of cortic...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
دوره 17 7 شماره
صفحات -
تاریخ انتشار 2014